Eversource Q1 2026 slides: earnings beat masks regulatory headwinds

Eversource beat Q1 expectations with non-GAAP EPS of $1.73 and revenue of $4.5B versus $4.08B forecast, but cut 2026 EPS guidance to $4.57-$4.72 from $4.80-$4.95 after a March FERC ROE ruling reduced allowed returns on ISO-New England transmission to 9.57% from 10.57%. The company also highlighted progress on de-risking initiatives, including the Aquarion sale, 95% completion of Revolution Wind, and improved credit metrics, though a major February blizzard and related storm-cost recovery remain key factors. Shares were down 2.9% premarket on regulatory and guidance concerns.

Analysis

The market is treating this as a classic utility de-rating event, but the second-order issue is not the one-quarter EPS cut — it’s the implied repricing of regulatory duration risk across the New England utility complex. When the allowed return resets lower after a long legal process, investors usually assume the pain is finite; in practice, the bigger effect is that every pending or future rate case gets discounted harder, especially where capital-heavy transmission spending depends on political goodwill rather than just asset growth.

That said, the selloff may be over-extended if the market is conflating headline ROE compression with balance-sheet fragility. The company’s improved credit cushion materially reduces near-term equity issuance risk, which is important because utilities often get punished twice: first on earnings, then again on dilution fears. If management can keep financing mostly debt-funded through storm securitization and operating cash flow, the earnings hit is more likely to be a valuation multiple issue than a solvency issue.

The real catalyst stack is asymmetrical over the next 6-18 months: Aquarion monetization, CL&P rate case timing, and the completion of the offshore wind project all have potential to shift sentiment, but none are immediate enough to protect the stock from being a bond proxy in a rising-rate tape. The contrarian view is that the market may be underestimating how much of the 2026-2030 capex program is self-help for earnings growth; once the regulatory noise fades, the base-rate + capital recovery combination can re-accelerate EPS without requiring heroic load growth assumptions.

Key Decisions for Investors

• Short-term: avoid chasing ES weakness; wait for a better entry after the next regulatory headline. Near-term downside remains tied to headline risk, but the bond-like balance sheet should cap panic selling.
• Longer-duration bullish expression: buy ES Jan-2027 or Jan-2028 call spreads on further weakness to capture recovery from Aquarion/CL&P catalysts while limiting carry cost; attractive if the stock overshoots below the low-$60s.
• Pair trade: long ES / short a more rate-sensitive utility with weaker balance-sheet momentum over the next 3-6 months. The thesis is ES can re-rate on credit improvement even if allowed ROEs stay pressured.
• If you want cleaner regulatory beta, reduce exposure until the CL&P case and Aquarion process are resolved; the next 2 quarters are likely to be headline-driven rather than fundamentals-driven.
• Monitor for a post-selloff stabilization above the revised guidance midpoint; if ES holds after the market digests the ROE cut, that is the signal to add ahead of 2027 catalyst realization.